Ernexa Therapeutics (ERNA) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to 0.58.
- Ernexa Therapeutics' Equity Ratio rose 10983.46% to 0.58 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58, marking a year-over-year increase of 10983.46%. This contributed to the annual value of 0.32 for FY2024, which is 61031.64% up from last year.
- According to the latest figures from Q3 2025, Ernexa Therapeutics' Equity Ratio is 0.58, which was up 10983.46% from 0.59 recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Equity Ratio ranged from a high of 0.83 in Q2 2021 and a low of 5.88 during Q3 2024
- Its 5-year average for Equity Ratio is 0.05, with a median of 0.45 in 2022.
- Over the last 5 years, Ernexa Therapeutics' Equity Ratio had its largest YoY gain of 61031.64% in 2024, and its largest YoY loss of 872700.14% in 2024.
- Quarter analysis of 5 years shows Ernexa Therapeutics' Equity Ratio stood at 0.8 in 2021, then crashed by 32.1% to 0.54 in 2022, then plummeted by 91.64% to 0.05 in 2023, then surged by 610.32% to 0.32 in 2024, then soared by 79.17% to 0.58 in 2025.
- Its last three reported values are 0.58 in Q3 2025, 0.59 for Q2 2025, and 1.18 during Q1 2025.